Skip to main content

Table 5 Comparison of Fatigue and QoL outcomes in mCRPC patients

From: PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study

  HT
(n = 75)
AAP < 3 months (n = 33) AAP ≥ 3 months (n = 43) p-value p-value AAP ≥ 3 months vs AAP < 3 months p-value
AAP ≥ 3 months vs HT
Fatigue intensity (BFI item 3) 3.0 (0.0–10.0) 4.0 (0.0–8.0) 2.0 (0.0–9.0) 0.125a 0.243 0.043
Fatigue severity, n (%)     0.039
No fatigue 15 (20.0) 10 (30.3) 13 (30.2)
Mild fatigue 29 (38.7) 8 (24.2) 19 (44.2)
Moderate fatigue 18 (24.0) 14 (42.4) 9 (20.9)
Severe fatigue 13 (17.3) 1 (3.0) 2 (4.7)
Interference (BFI item 4A-4F) 2.7 (0.0–9.0) 2.7 (0.0–7.0) 1.8 (0.0–10.0) 0.106b 0.473 0.04
FACT-G overall score 77.0 (24.7–101.0) 81.0 (35.0–101.0) 83.0 (38.0–103.0) 0.121c 0.429 0.046
FACT-P overall score 108.3 (50.7–140.0) 114.3 (57.0–137.0) 117.0 (61.0–138.0) 0.052d 0.402 0.018
Physical WB 22.0 (4.0–28.0) 24.0 (12.0–28.0) 24.0 (9.0–28.0) 0.031e 0.643 0.014
Social / Family WB 21.0 (3.0–28.0) 21.0 (2.0–28.0) 20.0 (11.0–28.0) 0.834
Emotional WB 17.0 (3.0–24.0) 17.0 (7.0–23.0) 18.0 (7.0–23.0) 0.727
Functional WB 17.0 (0.0–28.0) 19.0 (3.0–27.0) 21.0 (6.0–28.0) 0.041f 0.054 0.017
Prostate cancer subscale 30.0 (11.0–42.0) 32.0 (17.0–43.0) 34.0 (20.0–43.0) 0.029g 0.462 0.008
  1. Data are expressed as median (IQR), unless otherwise stated
  2. AAP Abiraterone Acetate-prednisone, HT traditional hormone therapy, IQR interquartile range, WB well-being